Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8405)
All Articles published online
|
Publishing Process of This Article
|
Aug 6, 2022 (publication date) through Dec 4, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Wang Z, Wu Q, Wang Q. Effect of celecoxib on improving depression: A systematic review and meta-analysis. World J Clin Cases 2022; 10(22): 7872-7882 [PMID: 36158469 DOI: 10.12998/wjcc.v10.i22.7872] |
|
|
|
| ©2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Wang Z, Wu Q, Wang Q. Effect of celecoxib on improving depression: A systematic review and meta-analysis. World J Clin Cases 2022; 10(22): 7872-7882 [PMID: 36158469 DOI: 10.12998/wjcc.v10.i22.7872] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i22/7872.htm |
| Number | Citing Articles |
| 1 |
Marianela Evelyn Traetta, Adriano Maia Chaves Filho, Elizabeth Toyin Akinluyi, Marie-Ève Tremblay. Microglia. Advances in Neurobiology 2024; 37: 457 doi: 10.1007/978-3-031-55529-9_26
|
| 2 |
Rui Sun, Meng-Yu Tang, Dan Yang, Yan-Yi Zhang, Yi-Heng Xu, Yong Qiao, Bin Yu, Shu-Xia Cao, Hao Wang, Hui-Qian Huang, Hong Zhang, Xiao-Ming Li, Hong Lian. C3aR in the medial prefrontal cortex modulates the susceptibility to LPS-induced depressive-like behaviors through glutamatergic neuronal excitability. Progress in Neurobiology 2024; 236: 102614 doi: 10.1016/j.pneurobio.2024.102614
|
| 3 |
Hui Zhao, Larissa Tao, Cheng Tang, Wa Cai, Weidong Shen. Do immune system and microbiome–gut–brain axis interactions associate with major depressive disorder?. Journal of Translational Medicine 2025; 23(1) doi: 10.1186/s12967-025-07176-w
|
| 4 |
Monika Dominiak, Adam Gędek, Michalina Sikorska, Paweł Mierzejewski, Marcin Wojnar, Anna Z. Antosik-Wójcińska. Acetylsalicylic Acid and Mood Disorders: A Systematic Review. Pharmaceuticals 2022; 16(1): 67 doi: 10.3390/ph16010067
|
| 5 |
Yishu Yin, Ting Ju, Deyong Zeng, Fangyuan Duan, Yuanbing Zhu, Junlian Liu, Yongzhi Li, Weihong Lu. “Inflamed” depression: A review of the interactions between depression and inflammation and current anti-inflammatory strategies for depression. Pharmacological Research 2024; 207: 107322 doi: 10.1016/j.phrs.2024.107322
|
| 6 |
Urszula Bąk, Anna Krupa. Challenges and Opportunities for Celecoxib Repurposing. Pharmaceutical Research 2023; 40(10): 2329 doi: 10.1007/s11095-023-03571-4
|
| 7 |
Yu-qi Chen, Jun-rui Ye, Sha-sha Wang, Ye Peng, Run Zhou, Ruo-lan Yuan, Wen-fei Wang, Shi-feng Chu, Zhao Zhang, Nai-hong Chen. Esflurbiprofen exerts a fast-onset antidepressant effect by blocking SERT-nNOS interaction. Acta Pharmacologica Sinica 2025; doi: 10.1038/s41401-025-01666-9
|
| 8 |
Mario Pinzi, Andrea Fagiolini, Despoina Koukouna, Giacomo Gualtieri, Maria Beatrice Rescalli, Caterina Pierini, Simone Pardossi, Benjamin Patrizio, Alessandro Cuomo. Inflammatory and Immune Biomarkers in Mood Disorders: From Mechanistic Pathways to Clinical Translation. Cells 2025; 14(19): 1558 doi: 10.3390/cells14191558
|
| 9 |
Adam Gędek, Zofia Szular, Anna Z. Antosik, Paweł Mierzejewski, Monika Dominiak. Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine 2023; 12(10): 3497 doi: 10.3390/jcm12103497
|
| 10 |
Ana Salomé Correia, Nuno Vale. Advancements Exploring Major Depressive Disorder: Insights on Oxidative Stress, Serotonin Metabolism, BDNF, HPA Axis Dysfunction, and Pharmacotherapy Advances. International Journal of Translational Medicine 2024; 4(1): 176 doi: 10.3390/ijtm4010010
|
| 11 |
Mohammad M Khan, Zaw Ali Khan, Mohsin Ali Khan. Metabolic complications of psychotropic medications in psychiatric disorders: Emerging role of <i>de novo</i> lipogenesis and therapeutic consideration. World Journal of Psychiatry 2024; 14(6): 767-783 doi: 10.5498/wjp.v14.i6.767
|
| 12 |
Shivangini Singh, Anil Nischal, Anuradha Nischal, Satyendra Kumar Singh, Vipul Singh, Adarsh Tripathi. Exploring early add-on celecoxib treatment in OCD: Results from a preliminary randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology 2025; doi: 10.1177/02698811251389556
|
| 13 |
Xiao Feng, Min Jia, Meng Cai, Tong Zhu, Kenji Hashimoto, Jian-Jun Yang. Central-peripheral neuroimmune dynamics in psychological stress and depression: insights from current research. Molecular Psychiatry 2025; 30(10): 4881 doi: 10.1038/s41380-025-03085-y
|
| 14 |
Mohammad M Khan, Zaw Ali Khan, Mohsin Ali Khan, Gauri Pandey. Childhood insulin resistance and neural stem cell dysfunction in psychiatric disorders: Role of <i>de novo</i> lipogenesis and treatment perspectives. World Journal of Stem Cells 2025; 17(7): 106194 doi: 10.4252/wjsc.v17.i7.106194
|
| 15 |
Sahar Ansari, Hossein Sanjari Moghaddam, Fatemeh A. Basti, Mohammadreza Salehi, Shahin Akhondzadeh. Efficacy and safety of celecoxib monotherapy for treatment of moderate depressive symptoms following COVID-19 infection: A randomized, double-blind, placebo-controlled trial. Journal of Psychosomatic Research 2023; 174: 111471 doi: 10.1016/j.jpsychores.2023.111471
|
| 16 |
Sergey K. Zyryanov, Elena A. Baybulatova. Current challenges for therapy of comorbid patients: a new look at celecoxib. A review. Terapevticheskii arkhiv 2024; 96(5): 531 doi: 10.26442/00403660.2024.05.202769
|
| 17 |
Daniel Kinderlehrer. Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity. Neuropsychiatric Disease and Treatment 2025; : 141 doi: 10.2147/NDT.S500337
|
| 18 |
Kriti Sharma, Devendra Kumar, Nisha Chandna, Jitander K. Kapoor. Celecoxib Reimagined: Multifunctional Roles in Advanced Drug Delivery and Therapeutics. ChemistrySelect 2025; 10(31) doi: 10.1002/slct.202502652
|
| 19 |
A Halaris, A Sayed, M Hakimi, J Sinacore. Modulation of the inflammatory response exerts beneficial effects on anger in treatment-resistant bipolar depression. Journal of Affective Disorders Reports 2023; 13: 100602 doi: 10.1016/j.jadr.2023.100602
|
| 20 |
Ashish Verma, Anmol Kumar, Satendra Chauhan, Nisha Sharma, Anuradha Kalani, Prakash Chandra Gupta. Interconnections of screen time with neuroinflammation. Molecular and Cellular Biochemistry 2025; 480(3): 1519 doi: 10.1007/s11010-024-05123-9
|
| 21 |
Xenia Gonda, Gianluca Serafini, Peter Dome. Fight the Fire: Association of Cytokine Genomic Markers and Suicidal Behavior May Pave the Way for Future Therapies. Journal of Personalized Medicine 2023; 13(7): 1078 doi: 10.3390/jpm13071078
|
| 22 |
Bárbara Dicarlo Costa Braga, Bruna Teixeira da Costa, Katiene Rodrigues Menezes de Azevedo. Tratamento anti-inflamatório na depressão: uma revisão sistemática. Debates em Psiquiatria 2024; 14: 1 doi: 10.25118/2763-9037.2024.v14.1156
|
| 23 |
Erhan Kavakbasi, Emma Sampson, Natalie T. Mills, Hikaru Hori, Kathrin Schwarte, Christa Hohoff, K. Oliver Schubert, Scott R. Clark, Célia Fourrier, Bernhard T. Baune. Inflammation‐stratified augmentation of vortioxetine with celecoxib: Results from a double‐blind, randomized, placebo‐controlled trial in major depressive disorder. Journal of Neurochemistry 2024; 168(9): 1817 doi: 10.1111/jnc.15946
|
| 24 |
Cheng-gang Li, Lu-shan Xu, Liang Sun, Yu-hao Xu, Xiang Cao, Chen-chen Zhao, Sheng-nan Xia, Qing-xiu Zhang, Yun Xu. Xiangshao Granules Ameliorate Post-stroke Depression by Inhibiting Activation of Microglia and IDO1 Expression in Hippocampus and Prefrontal Cortex. Chinese Journal of Integrative Medicine 2025; 31(1): 28 doi: 10.1007/s11655-024-3903-5
|
| 25 |
Irina Goldina, Evgeniya Valerievna Markova, Mariya Aleksandrovna Knyazheva, Ivan Vladimirovich Savkin, Tamara Vladimirovna Shushpanova, Olga Sergeevna Anikeeva. MODERN APPROACHES TO THE DEPRESSION IMMUNOTHERAPY. Reviews on Clinical Pharmacology and Drug Therapy 2025; doi: 10.17816/RCF680652
|
| 26 |
Run Zhou, Ruolan Yuan, Junrui Ye, Shasha Wang, Yuqi Chen, Xiaofen Zhou, Shifeng Chu, Zhao Zhang, Naihong Chen. Trans-cinnamaldehyde alleviates IFN-α-induced depressive-like behaviors by restoring astrocytic Cx43 gap junction. International Immunopharmacology 2025; 167: 115741 doi: 10.1016/j.intimp.2025.115741
|
| 27 |
Marcel Bertsch-Gout, Anthony T. Reder, Royce Lee. Stress: Immunology and Inflammation. 2024; : 147 doi: 10.1016/B978-0-12-817558-3.00017-2
|
| 28 |
Bruna R. Kouba, Laura de Araujo Borba, Pedro Borges de Souza, Joana Gil-Mohapel, Ana Lúcia S. Rodrigues. Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets. Cells 2024; 13(5): 423 doi: 10.3390/cells13050423
|
| 29 |
Anna Łysik, Katarzyna Logoń, Aleksandra Szczygieł, Julia Wołoszczak, Martyna Wrześniewska, Jerzy Leszek. Innovative approaches in the treatment-resistant depression: exploring different therapeutic pathways. GeroScience 2025; 47(4): 5543 doi: 10.1007/s11357-025-01615-8
|